Edition:
United States

AMAG Pharmaceuticals Inc (AMAG.O)

AMAG.O on Nasdaq

15.60USD
20 Oct 2017
Change (% chg)

$-0.45 (-2.80%)
Prev Close
$16.05
Open
$16.15
Day's High
$16.25
Day's Low
$15.20
Volume
1,759,860
Avg. Vol
844,158
52-wk High
$36.83
52-wk Low
$15.20

Chart for

About

AMAG Pharmaceuticals, Inc. is a pharmaceutical company. The Company's segment is the manufacture, development and commercialization of products and services for use in treating various conditions, with a focus on maternal health, anemia management and cancer supportive care. Its offerings focus on maternal health, anemia... (more)

Overall

Beta: 0.86
Market Cap(Mil.): $550.50
Shares Outstanding(Mil.): 35.29
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 31.71 16.52
EPS (TTM): -- -- --
ROI: -- 14.89 11.32
ROE: -- 16.15 15.18

BRIEF-Amag Pharmaceuticals announces U.S. FDA filing acceptance

* Amag announces U.S. FDA filing acceptance and six-month review of Feraheme® (Ferumoxytol) for the treatment of all adult patients with iron deficiency anemia

Aug 31 2017

BRIEF-Amag Pharmaceuticals Q2 loss per share $0.40

* Amag pharmaceuticals announces second quarter 2017 financial results and provides corporate update

Aug 03 2017

BRIEF-Amag completes feraheme FDA submission for the treatment of all adult patients with iron deficiency anemia

* Amag completes Feraheme® (ferumoxytol) FDA submission for the treatment of all adult patients with iron deficiency anemia

Aug 03 2017

BRIEF-Amag Pharmaceuticals announces commercial availability of Intrarosa (prasterone) at U.S. pharmacies

* Says announces commercial availability of intrarosa (prasterone) at U.S. pharmacies

Jul 24 2017

BRIEF-Amag reports U.S. FDA acceptance of supplemental new drug application for Makena

* Amag announces U.S. FDA filing acceptance of supplemental new drug application for makena® (hydroxyprogesterone caproate injection) subcutaneous auto-injector

Jun 26 2017

BRIEF-Camber Capital Management LLC reports 7.13 pct passive stake in AMAG Pharmaceuticals

* Camber Capital Management LLC reports 7.13 percent passive stake in AMAG Pharmaceuticals Inc as on May 04, 2017 - SEC filing Source text (http://bit.ly/2rj6Y6h) Further company coverage:

May 15 2017

BRIEF-Amag Pharmaceuticals Inc says increased size of offering to $300 mln

* Amag Pharmaceuticals announces pricing of $300 million of 3.25% convertible senior notes due 2022

May 05 2017

BRIEF-AMAG Pharma announces proposed offering of $250 mln of convertible senior notes due 2022

* AMAG Pharmaceuticals Inc announces proposed offering of $250 million of convertible senior notes due 2022

May 03 2017

BRIEF-AMAG Pharmaceuticals says positive topline data from Feraheme label expansion study

* Announces positive topline data from phase 3 feraheme® (ferumoxytol) label expansion study

May 02 2017

BRIEF-AMAG Pharmaceuticals posts Q1 loss per share $1.06

* AMAG Pharmaceuticals announces first quarter 2017 financial results and provides corporate update

May 02 2017

Earnings vs. Estimates